Company: BIAF
Filing Date: 2025-08-29
Form Type: S-1
Source: 0001641172-25-025990
Chunk: 16

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-08-29
Form: S-1
Chunk 16
---
23 per share and (ii) warrants (the “Private Warrants”) to purchase up to 6,714,780 shares of the Company’s Common Stock at an exercise price of $0.352 per share of Common Stock.

We received aggregate gross proceeds from the August 2025 Private Placement of approximately $1.2 million, before deducting fees payable to WallachBeth as placement agent and other estimated offering expenses payable by us. The issuance of the Series B Preferred Stock, the Conversion Shares, the Private Warrants and the Private Warrant Shares were not registered under the Securities Act. The Private Warrants will be exercisable commencing on the effective date of stockholder approval of the issuance of the Private Warrant Shares issuable upon exercise of the Private Warrants (the “Private Warrant Stockholder Approval Date” and together with the Inducement Stockholder Approval Date, the “Stockholder Approval Date”) and will expire on the fifth anniversary of the Private Warrant Stockholder Approval Date.

WallachBeth acted as the placement agent on a “reasonable best efforts” basis in connection with the August 2025 Private Placement and pursuant to the Placement Agency Agreement and received a cash fee of 7.5% of the aggregate purchase price paid by the Investors in the August 2025 Private Placement and reimbursement of certain out-of-pocket expenses up to a maximum of $65,000. As additional compensation to WallachBeth, in connection with the August 2025 Private Placement, we issued the Placement Agent Warrants to purchase an aggregate of 129,130 shares of Common Stock, at an exercise price per share equal to $0.352. The Placement Agent Warrants have substantially the same terms as the Private Warrants, including that the Placement Agent Warrants have an exercise price equal to $0.352 per share, except that they were immediately exercisable upon issuance and expire on the five-year anniversary of the date of issuance.

| 9 |

Pursuant to the Registration Rights Agreement, we agreed to file a resale registration statement on Form S-1 to register the resale of the Private Warrant Shares as soon as practicable (and in any event within 15 calendar days following the date of the Registration Rights Agreement), and to use commercially reasonable efforts to have such registration statement declared effective by the Commission and to keep such registration statement effective at all times until the Investors no longer own any Series B Preferred Stock, Conversion Shares, Private Warrants or Private Warrant Shares. Pursuant to the Placement Agency Agreement, the